Total amount raised
$402M
Latest funding date
9/1/2026
Location
AvenCell has successfully raised funding over five rounds, with the latest being a September 2026 royalty and equity financing of up to $47 million led by Ligand Pharmaceuticals. The company is dedicated to developing next-generation immunotherapies for hard-to-treat cancers, utilizing proprietary platforms like the Universal Switchable CAR and Allogeneic platforms.
What Is AvenCell?
AvenCell Therapeutics, based in Watertown, Massachusetts, is a private company in the biotechnology and immunotherapy industry. The company is dedicated to developing next-generation immunotherapies for hard-to-treat cancers, utilizing proprietary platforms like the Universal Switchable CAR and Allogeneic platforms.
Founded in June 2021 with Blackstone Life Sciences as its sole founding investor, AvenCell has grown to employ between 51 and 100 people. The company is guided by a distinguished board of industry experts and has raised capital across multiple rounds including private equity, a Series B, and grants, with notable investors including Blackstone Life Sciences, Novo Holdings, F-Prime Capital, and AMED.
How Much Funding Has AvenCell Raised?
- Series A / Founding Round
- Amount Raised: USD 250,000,000 (committed capital)
- Date: June 2021
- Lead Investors: Blackstone Life Sciences (sole founding investor)
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To launch AvenCell and fund the development of autologous and allogeneic universal CAR T-cell therapies for immuno-oncology and autoimmune diseases.
- Grant Round (Europa)
- Amount Raised: Undisclosed
- Date: February 2023
- Lead Investors: Europa
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To support continued development of AvenCell's CAR-T programs.
- Series B Round
- Amount Raised: USD 112,000,000
- Date: October 2024
- Lead Investors: Novo Holdings
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To accelerate the clinical validation of AvenCell's Universal Switchable CAR-T cell therapy platform for hematologic malignancies and autoimmune diseases.
- Grant Round (AMED)
- Amount Raised: Up to USD 40,000,000
- Date: June 2025
- Lead Investors: AMED (Japan Agency for Medical Research and Development)
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To advance the worldwide development of AVC203, an IND-stage, dual-antigen (CD19 & CD20) allogeneic CAR-T therapy for B-cell Lymphomas.
- Royalty and Equity Financing (Ligand)
- Amount Raised: Up to USD 47,000,000
- Date: September 2026
- Lead Investors: Ligand Pharmaceuticals
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To advance AvenCell's pipeline, including AVC-201 for relapsed/refractory acute myeloid leukemia and AVC-203 for B-cell malignancies.
Total amount raised: At least USD 402,000,000 based on disclosed funding (USD 250M founding round + USD 112M Series B + up to USD 40M AMED grant; the February 2023 Europa grant amount was not publicly disclosed). Current valuation: Not publicly disclosed. The September 2026 Ligand financing of up to USD 47,000,000 is paid in milestone-based tranches and is not included in this total.
Key Investors
- Ligand Pharmaceuticals
- Details: Ligand Pharmaceuticals is a Nasdaq-listed biopharmaceutical company that funds drug development through royalty financing. It provided AvenCell's September 2026 financing of up to $47 million, combining royalty financing with a Series C equity commitment.
- Investment Focus Areas: Royalty financing and investment in late-stage and clinical biopharmaceutical programs
- Notable Investments: Not publicly disclosed
- Blackstone Life Sciences
- Details: Blackstone Life Sciences is the sole founding investor in AvenCell, committing $250 million at launch in June 2021. They continued participation in the Series B financing round.
- Investment Focus Areas: Life sciences, healthcare, biotechnology.
- Notable Investments: AvenCell.
- Novo Holdings
- Details: Novo Holdings is a global life sciences investor that led AvenCell's $112 million Series B in October 2024. Michael Bauer, a partner at Novo Holdings, joined AvenCell's Board of Directors.
- Investment Focus Areas: Life sciences, healthcare, biotechnology.
- Notable Investments: Not publicly disclosed.
- F-Prime Capital
- Details: F-Prime Capital is a venture capital firm that invests in healthcare and life sciences. Nihal Sinha, a partner at F-Prime Capital, joined AvenCell's Board of Directors as part of the Series B round.
- Investment Focus Areas: Healthcare, life sciences, biotechnology.
- Notable Investments: Not publicly disclosed.
- Eight Roads Ventures Japan
- Details: Eight Roads Ventures Japan is a venture capital firm focused on healthcare and technology. They participated as a new investor in AvenCell's Series B financing.
- Investment Focus Areas: Healthcare, technology, venture capital.
- Notable Investments: Not publicly disclosed.
- AMED
- Details: The Japan Agency for Medical Research and Development (AMED) awarded AvenCell's subsidiary, AvenCell Japan, a non-dilutive grant of up to $40 million in June 2025 to support the worldwide development of AVC203.
- Investment Focus Areas: Medical research, healthcare innovation, biotechnology.
- Notable Investments: AvenCell.
What's Next for AvenCell?
With a robust $112 million Series B financing, AvenCell is poised to advance its Universal Switchable CAR-T cell therapy platform. This innovative technology aims to treat a wide range of hematologic malignancies and autoimmune diseases, offering significant growth potential in the biotechnology sector. The company plans to introduce several pipeline candidates over the next two years, addressing unmet patient needs and expanding its market presence.
Future fundraising opportunities appear promising, given the strong backing from high-profile investors like Novo Holdings and F-Prime Capital. As AvenCell progresses through clinical trials, additional funding rounds may be necessary to support further development and commercialization efforts. However, the company faces challenges such as clinical validation, regulatory approvals, and competition from other biotech firms. Navigating these hurdles will be crucial for AvenCell's continued success and potential for strategic partnerships or acquisitions.
Use Clay to Get Funding Data
Sales professionals, leverage Clay's platform to access comprehensive fundraising data on companies like AvenCell and gather other critical business insights. Sign up for free to start transforming your sales strategy today.
